Source comparison
BPC-157 Skin Health Research: Comparison of Study Protocols
Rat excisional wound (Zagreb, 2011) 10 µg/kg daily Intraperitoneal injection Re-epithelialization rate 37% faster closure by day 7 VEGF upregulation, increased capillary density Robust preclinical evidence but limited to acute wounds. Chronic wound healing not
This comparison does not assign a generated winner or score.
- Rat excisional wound (Zagreb, 2011)
- 10 µg/kg daily
- Intraperitoneal injection
- Re-epithelialization rate
- 37% faster closure by day 7
- VEGF upregulation, increased capillary density
- Robust preclinical evidence but limited to acute wounds. Chronic wound healing not assessed
- Diabetic rat wound model (2018)
- 10 mg/kg daily
- Subcutaneous at wound margin
- Tensile strength at day 14
- Restored to non-diabetic baseline
- Enhanced fibroblast migration, reduced oxidative stress markers
- Suggests potential for impaired healing contexts but dose 1000× higher than earlier studies raises translation concerns
- Mouse burn injury model (2014)
- 10 µg/kg twice daily
- Topical application in hydrogel
- Inflammatory cytokine reduction
- 28% reduction in wound area by day 5
- Modulation of TNF-α and IL-6 expression
- Topical delivery shows efficacy but hydrogel formulation details not disclosed. Reproducibility uncertain
- In vitro human fibroblast assay (2020)
- 1–100 ng/mL
- Culture medium supplementation
- Cell migration in scratch assay
- Dose-dependent increase, peak at 10 ng/mL
- ERK1/2 and FAK phosphorylation
- Confirms direct fibroblast effects but in vitro concentration may not reflect achievable tissue levels in vivo